SBI Okasan Asset Management Co.Ltd. Makes New $427,000 Investment in Celldex Therapeutics, Inc. $CLDX

SBI Okasan Asset Management Co.Ltd. bought a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 16,400 shares of the biopharmaceutical company’s stock, valued at approximately $427,000.

Several other hedge funds have also added to or reduced their stakes in the stock. Intech Investment Management LLC boosted its holdings in Celldex Therapeutics by 8.4% in the fourth quarter. Intech Investment Management LLC now owns 33,499 shares of the biopharmaceutical company’s stock worth $910,000 after acquiring an additional 2,608 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in Celldex Therapeutics by 1.1% in the fourth quarter. Fisher Asset Management LLC now owns 937,158 shares of the biopharmaceutical company’s stock worth $25,453,000 after acquiring an additional 10,001 shares in the last quarter. PSP Research LLC bought a new position in shares of Celldex Therapeutics during the fourth quarter valued at $553,000. Handelsbanken Fonder AB lifted its holdings in shares of Celldex Therapeutics by 19.9% during the fourth quarter. Handelsbanken Fonder AB now owns 25,900 shares of the biopharmaceutical company’s stock valued at $703,000 after purchasing an additional 4,300 shares in the last quarter. Finally, Profund Advisors LLC lifted its holdings in shares of Celldex Therapeutics by 99.3% during the fourth quarter. Profund Advisors LLC now owns 42,454 shares of the biopharmaceutical company’s stock valued at $1,153,000 after purchasing an additional 21,149 shares in the last quarter.

Celldex Therapeutics Stock Down 0.9%

Shares of CLDX opened at $31.43 on Friday. The business has a 50-day simple moving average of $32.16 and a two-hundred day simple moving average of $28.49. The stock has a market cap of $2.47 billion, a price-to-earnings ratio of -7.38 and a beta of 0.98. Celldex Therapeutics, Inc. has a 52 week low of $18.55 and a 52 week high of $35.79.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.80 million. On average, equities analysts anticipate that Celldex Therapeutics, Inc. will post -4.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CLDX. Stifel Nicolaus reaffirmed a “buy” rating and set a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. Barclays upped their price target on Celldex Therapeutics from $45.00 to $48.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Wall Street Zen raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. The Goldman Sachs Group upped their price target on Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Monday, March 2nd. Finally, Wolfe Research raised Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price target on the stock in a report on Monday, March 23rd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $49.78.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.